Literature DB >> 12883525

Osteoinduction by ex vivo adenovirus-mediated BMP2 delivery is independent of cell type.

Z Gugala1, E A Olmsted-Davis, F H Gannon, R W Lindsey, A R Davis.   

Abstract

The objective of the study was to analyze and compare the abilities of various human cell types with inherently dissimilar osteogenic potentials to induce heterotopic bone formation following ex vivo transduction with two distinct adenoviral vectors encoding bone morphogenetic protein type 2 (BMP2). The cells comprised primary human bone marrow mesenchymal stem cells (BM-MSCs), primary human skin fibroblasts (SFs), and a human diploid fetal lung cell line (MRC-5). The vectors included adenovirus type 5 or a chimeric adenovirus type 5 with the fiber gene of adenovirus type 35 (Ad5F35-BMP2), both demonstrating significantly different expression of BMP2 in vitro. The experimental groups consisted of the three human cell types transduced with each of the two adenoviral vectors. Using nonobese diabetic severe combined immunodeficiency (NOD/SCID) mice, the transduced cells were injected intramuscularly following ex vivo adenoviral transduction. The nature and extent of heterotopic bone formation were analyzed radiographically and histologically. At 14 days postinjection, abundant, highly mineralized bone was formed in mice injected with Ad5F35-BMP2-transduced cells irrespective of the cell type. There was no statistically significant difference in the amount of bone formed between BM-MSCs, SFs, and MRC-5 cells transduced with Ad5F35-BMP2, as assessed from bone surface area on biplanar plain radiography. Substantially lesser amounts or no bone could be detected in mice injected with cells transduced with Ad5-BMP2. Immunohistochemical analysis confirmed the presence of human cells in muscle as early as 2 days postdelivery; however, at 6-7 days after injection, the transduced cells could not be detected in surrounding muscle, or in the heterotopic bone, indicating the host origin of the newly formed bone. The results of the study demonstrate no significant difference in osteoinductive properties between BM-MSCs, SFs, and MRC-5 cells transduced ex vivo with the same type of adenovirus encoding BMP2. The level of BMP2 expression appears to be a crucial factor determining the extent of heterotopic bone formation and was significantly affected by the type of adenovirus used. In the cell types studied, Ad5F35-BMP2 was more efficacious than Ad5-BMP2 in providing adequate levels of BMP2 for efficient osteoinduction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883525     DOI: 10.1038/sj.gt.3302006

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  25 in total

Review 1.  Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases.

Authors:  Jakob Reiser; Xian-Yang Zhang; Charles S Hemenway; Debasis Mondal; Leena Pradhan; Vincent F La Russa
Journal:  Expert Opin Biol Ther       Date:  2005-12       Impact factor: 4.388

2.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

Review 3.  Human artificial chromosomes for gene delivery and the development of animal models.

Authors:  Yasuhiro Kazuki; Mitsuo Oshimura
Journal:  Mol Ther       Date:  2011-07-12       Impact factor: 11.454

4.  Hypoxic adipocytes pattern early heterotopic bone formation.

Authors:  Elizabeth Olmsted-Davis; Francis H Gannon; Mustafa Ozen; Michael M Ittmann; Zbigniew Gugala; John A Hipp; Kevin M Moran; Christine M Fouletier-Dilling; Shannon Schumara-Martin; Ronald W Lindsey; Michael H Heggeness; Malcolm K Brenner; Alan R Davis
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

5.  Far-red fluorescence gene reporter tomography for determination of placement and viability of cell-based gene therapies.

Authors:  Yujie Lu; Chinmay D Darne; I-Chih Tan; Banghe Zhu; Mary A Hall; Zawaunyka W Lazard; Alan R Davis; Lashan Simpson; Eva M Sevick-Muraca; Elizabeth A Olmsted-Davis
Journal:  Opt Express       Date:  2013-10-07       Impact factor: 3.894

6.  Sensory nerve induced inflammation contributes to heterotopic ossification.

Authors:  Elizabeth Salisbury; Eric Rodenberg; Corinne Sonnet; John Hipp; Francis H Gannon; Tegy J Vadakkan; Mary E Dickinson; Elizabeth A Olmsted-Davis; Alan R Davis
Journal:  J Cell Biochem       Date:  2011-10       Impact factor: 4.429

7.  Hydrogel microsphere encapsulation of a cell-based gene therapy system increases cell survival of injected cells, transgene expression, and bone volume in a model of heterotopic ossification.

Authors:  Ronke M Olabisi; Zawaunyka W Lazard; Christy L Franco; Mary A Hall; Sun Kuk Kwon; Eva M Sevick-Muraca; John A Hipp; Alan R Davis; Elizabeth A Olmsted-Davis; Jennifer L West
Journal:  Tissue Eng Part A       Date:  2010-09-01       Impact factor: 3.845

8.  Cell-based gene therapy for repair of critical size defects in the rat fibula.

Authors:  Zawaunyka W Lazard; Michael H Heggeness; John A Hipp; Corinne Sonnet; Angie S Fuentes; Rita P Nistal; Alan R Davis; Ronke M Olabisi; Jennifer L West; Elizabeth A Olmsted-Davis
Journal:  J Cell Biochem       Date:  2011-06       Impact factor: 4.429

9.  Encapsulation of Adenovirus BMP2-Transduced Cells with PEGDA Hydrogels Allows Bone Formation in the Presence of Immune Response.

Authors:  Pedro Alvarez-Urena; Eleanor Davis; Corinne Sonnet; Gabrielle Henslee; Zbigniew Gugala; Edward V Strecker; Laura J Linscheid; Maude Cuchiara; Jennifer West; Alan Davis; Elizabeth Olmsted-Davis
Journal:  Tissue Eng Part A       Date:  2017-01-25       Impact factor: 3.845

10.  Transient brown adipocyte-like cells derive from peripheral nerve progenitors in response to bone morphogenetic protein 2.

Authors:  Elizabeth A Salisbury; Zawaunyka W Lazard; Eroboghene E Ubogu; Alan R Davis; Elizabeth A Olmsted-Davis
Journal:  Stem Cells Transl Med       Date:  2012-11-26       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.